| Mrs Dawn Christine Tobin-holt, PT | |
|
217 Route 303, Valley Cottage, NY 10989-2533 | |
| (845) 268-6010 | |
| (845) 268-6011 |
| Full Name | Mrs Dawn Christine Tobin-holt |
|---|---|
| Gender | Female |
| Speciality | Physical Therapist - Pediatrics |
| Location | 217 Route 303, Valley Cottage, New York |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1003072315 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 2251P0200X | Physical Therapist - Pediatrics | 012837-1 (New York) | Primary |
| Provider Name | Pediatric Physical And Occupational Therapy Of Hudson Valley Pllc |
|---|---|
| Provider Type | Part B Supplier - Physical/occupational Therapy Group In Private Practice |
| Provider Identifiers | NPI Number: 1831418359 PECOS PAC ID: 8628318300 Enrollment ID: O20190315000058 |
News Archive
Mesenchymal stem cells (MSCs), are a newly emerging cellular therapy being tested in approximately 250 clinical trials worldwide to help repair damaged tissues, such as injured heart muscle following a heart attack. The problem is that when culture-expanded MSCs are injected into the circulation, they have trouble gaining access to the inflamed tissues-exactly where their help is needed.
Aphios Corporation today announced that it has been awarded a RC-1 Challenge grant (No. 1RC1HL102822-01) from the National Heart, Lung, and Blood Institute (NHLBI), National Institute of Health's (NIH) American Recovery and Reinvestment Act (ARRA) funds to develop a generally-applicable pathogen inactivation technology for blood products.
Acurian announced today that it has been granted EU privacy certification from TRUSTe, the leading Internet privacy and security assurance program. TRUSTe will provide Acurian with third-party privacy claims and dispute resolution services, which will allow Acurian to broaden its patient recruitment and retention services in Europe. Acurian will display the TRUSTe seal of assurance on its websites.
AstraZeneca today announced that the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have accepted regulatory submissions for review of the investigational drug vandetanib in the treatment of patients with advanced medullary thyroid cancer (MTC). The FDA also granted priority review status for the new drug application and set a Prescription Drug User Fee Act (PDUFA) action date of 7 January 2011.
› Verified 2 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Mrs Dawn Christine Tobin-holt, PT 113 Hunt Ave, Pearl River, NY 10965-1881 Ph: (845) 735-1227 | Mrs Dawn Christine Tobin-holt, PT 217 Route 303, Valley Cottage, NY 10989-2533 Ph: (845) 268-6010 |
News Archive
Mesenchymal stem cells (MSCs), are a newly emerging cellular therapy being tested in approximately 250 clinical trials worldwide to help repair damaged tissues, such as injured heart muscle following a heart attack. The problem is that when culture-expanded MSCs are injected into the circulation, they have trouble gaining access to the inflamed tissues-exactly where their help is needed.
Aphios Corporation today announced that it has been awarded a RC-1 Challenge grant (No. 1RC1HL102822-01) from the National Heart, Lung, and Blood Institute (NHLBI), National Institute of Health's (NIH) American Recovery and Reinvestment Act (ARRA) funds to develop a generally-applicable pathogen inactivation technology for blood products.
Acurian announced today that it has been granted EU privacy certification from TRUSTe, the leading Internet privacy and security assurance program. TRUSTe will provide Acurian with third-party privacy claims and dispute resolution services, which will allow Acurian to broaden its patient recruitment and retention services in Europe. Acurian will display the TRUSTe seal of assurance on its websites.
AstraZeneca today announced that the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have accepted regulatory submissions for review of the investigational drug vandetanib in the treatment of patients with advanced medullary thyroid cancer (MTC). The FDA also granted priority review status for the new drug application and set a Prescription Drug User Fee Act (PDUFA) action date of 7 January 2011.
› Verified 2 days ago
Dr. Jessica Lynn Mitchell, D.P.T. Physical Therapist Medicare: May Accept Medicare Assignments Practice Location: 7 New Lake Rd, Valley Cottage, NY 10989 Phone: 845-809-8176 | |
Dr. John Patrick Fahy, DPT Physical Therapist Medicare: Accepting Medicare Assignments Practice Location: 612 Corporate Way, Suite 7, Valley Cottage, NY 10989 Phone: 845-268-7800 Fax: 845-268-5037 | |
Samantha K Mcguire, Physical Therapist Medicare: May Accept Medicare Assignments Practice Location: 7 New Lake Rd, Valley Cottage, NY 10989 Phone: 845-809-8176 | |
Noreen Shimkus, Physical Therapist Medicare: Not Enrolled in Medicare Practice Location: 412 Storms Rd, Valley Cottage, NY 10989 Phone: 773-316-8177 | |
Kristine Ann Skinner, Physical Therapist Medicare: Accepting Medicare Assignments Practice Location: 704 Executive Blvd Ste H, Valley Cottage, NY 10989 Phone: 845-268-7800 | |
Nanda J Nevola, PT, PC Physical Therapist Medicare: Not Enrolled in Medicare Practice Location: Ta Ra Institute, 104 Lake Rd, Valley Cottage, NY 10989 Phone: 845-300-2847 Fax: 668-412-4528 |